Imfinzi Approved in the EU as First Perioperative Immunotherapy for Early Gastric and GEJ Cancers

Oncodaily·Mar 18

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Imfinzi has been approved in the eu for early gastric and gastroesophageal cancers as a perioperative immunotherapy. The approval appears to be a first of its kind in the eu for this type of treatment. Reports indicate the approval is for use in patients with these specific cancers, though details of the approval, such as the specific cancers and treatment combinations, are not entirely consistent across reports.

Full coverage

Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

AstraZeneca·Mar 16

AstraZeneca’s Imfinzi wins EU-first immunotherapy approval in early GI cancers

European Pharmaceutical Review·Mar 24

EU Approves AstraZeneca's Imfinzi Combo as First Perioperative Treatment for Early Gastric Cancer

Yahoo Finance UK·Mar 16

New EU approval for AstraZeneca’s Imfinzi

The Pharma Letter·Mar 16

AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers

PMLiVE·Mar 16

AstraZeneca’s Imfinzi Wins EU Approval for Early Gastric/GEJ Cancer

Oncodaily·Mar 19

Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

AstraZeneca·Nov 25

CHMP Recommends EU Approval of Perioperative Durvalumab for Muscle-Invasive Bladder Cancer

OncLive·May 27

View original report at Oncodaily ↗

Fetching the latest headlines…